DEMONSTRATION REPORT / NOVEMBER 2025

Factory Audit & Supplier Verification Report

A structured example of an on-site manufacturing review, with archival photographs and identifying information removed.

> IMPORTANT - DEMONSTRATION COPY. 14 November 2025 is an illustrative sample date, not the date of a verified audit. The factual observations below were adapted from a separate historical visit report dated 04 March 2021. This document is not evidence that YiwuQC conducted that original visit or a new audit in 2025.

01. Audit overview

Report reference	YQC-FA-SAMPLE-2025-11
Sample audit date	14 November 2025 (illustrative)
Inspector	Lee (sample name)
Supplier / site	Identity withheld for public demonstration
Location	Fujian Province, China; exact site details withheld
Primary product	Natamycin / food-additive manufacturing
Review type	Factory visit, business-document review and site observations

Executive assessment

The historical source describes a manufacturer with visible offices, laboratories, testing rooms, warehouse space and factory buildings. The company presented itself as a direct manufacturer and supplier. The visit did not include observation of production machinery in operation.

The most material qualification related to natamycin: documentation referenced food-additive production, while the supplier also discussed pharmaceutical/API applications. That distinction was not fully resolved by the records available during the visit.

SITE PHOTOGRAPHS (ARCHIVAL SOURCE)



Factory grounds



Laboratory work area

SECTION A / SITE INFORMATION

02. Factory profile

Company identity	Redacted in this public version
Legal representative	Not present during the historical visit
Year of establishment	2003 (reported)
Total personnel	Approximately 550 (reported)
Site area	Approximately 20,000 m² (reported)
Manufacturing scope	Food and feed additives, veterinary-related raw materials, premixes and related products, as described in the original report.
Supplier relationship	Presented as a direct manufacturer and supplier; original visit did not independently establish all commercial history.

03. Scope and site access

- Confirmation of the physical site and discussion of differences between the site address and the wording used in registration documents.
- Review of selected business, quality and production documents made available by the supplier.
- Walk-through of general facilities including offices, quality/regulatory areas, laboratory, testing rooms, warehouse and accessible exterior areas.
- Discussion of product status, licensing and information needed for potential export transactions.

> Access limitation. The inspector was not admitted to observe the production workshop in operation. According to the source report, the machinery was not running during the visit. Accordingly, production-line performance and process controls were not directly verified.

SECTION B / DOCUMENT VERIFICATION

04. Documents presented or discussed

The following reflects what the historical source report says was available. Listing a document here does not constitute independent authentication, approval or certification by YiwuQC.

Document / record	What the historical report records
Business and manufacturing licenses	Business and food-production licenses were referenced or shown. Certain document updates were reportedly in progress.
ISO 9001 certificate	A copy was provided; the report did not include a photo of the original certificate.
Product test report	A copy was provided; the source notes limited original-document photographic evidence.
Halal / Kosher certificates	Mentioned as additional supporting materials; scans were reportedly provided.
Veterinary-production license	Mentioned as part of the supplier documentation reviewed.
Drug Master File (DMF)	The supplier stated that a DMF existed for natamycin. The full file was not released to the visitor because of confidentiality restrictions.

Address and registration consistency

The source report says that the physical location visited matched the manufacturing site. However, the municipality had changed the formal address designation, and the supplier was updating documents to reflect the change. This issue would require fresh verification for a current order.

Commercial history

Statements about earlier deliveries to overseas customers were made verbally. The visit report says these statements were not supported by documentary records reviewed on-site.

SECTION C / PRODUCT-SPECIFIC REVIEW

05. Natamycin: reported status and gaps

Product category and intended use matter in assessing the suitability of a manufacturer for a particular destination market. In the original report, the supplier described natamycin in both food-additive and pharmaceutical/API contexts.

Topic	Finding from the source
Food-additive licensing	The factory supplied documents indicating natamycin was handled within a food-additive manufacturing framework.
Pharmaceutical/API status	The supplier discussed API use, but the full documentary basis for an API designation was not established during the visit.
GMP evidence	The historical report records that a GMP certificate specifically supporting the claimed natamycin status was not shown.
Manufacturing license	The inspector reviewed a copy rather than the original. The supplier said a renewal or update was in progress.
Destination-market acceptance	The report mentions overseas destinations and a question about CE documentation. It does not demonstrate compliance with current import or medicinal-product requirements.
Full DMF access	Not provided during the historical visit.

Interpretation. The archived observations should not be treated as a current compliance decision, or as evidence that a specific substance is suitable for pharmaceutical use. A buyer would need product- and destination-specific documentation, validated independently for the planned transaction.

SECTION D / SITE PHOTOGRAPHS

06. Facility and work areas

Selected archival photographs from the original report. Sensitive documents, business cards and identity photographs are excluded.



Factory grounds

Exterior overview



Office and meeting room

Administrative area



Laboratory benches

Visible testing facilities



Warehouse access

Storage area observed

Photographs reflect the historical source visit; they do not represent a verified visit in November 2025.

SECTION D / SITE PHOTOGRAPHS

06. Testing and laboratory facilities

Selected archival photographs from the original report. Sensitive documents, business cards and identity photographs are excluded.



Laboratory equipment

Analytical instruments



Testing instruments

Instrument station



Testing room

Visible sample-handling area



Entrance image

Identifying signage obscured

Photographs reflect the historical source visit; they do not represent a verified visit in November 2025.

SECTION E / AUDIT DECISION SUPPORT

07. Findings and conclusion

What the historical visit supports

- The site presented visible manufacturing premises, offices, laboratory/testing facilities and warehouse areas.
- The supplier provided or discussed business, manufacturing and quality documentation.
- The source report characterizes the enterprise as a manufacturer and direct supplier of products including natamycin.

What remained unverified

- Production equipment and process operation were not observed during the visit.
- A complete natamycin DMF and independent proof of certain claims were not provided.
- Pharmaceutical/API regulatory suitability for a particular destination market was not demonstrated by the materials available.

Sample conclusion. The original report indicates that the visited enterprise carried out permitted food-additive manufacturing activities and had visible facilities consistent with an operating manufacturer. However, it leaves important limitations around product-specific regulatory status and documentary evidence. A purchasing decision for regulated natamycin use should be preceded by current, independent verification.

08. Recommended follow-up

- Obtain current business, production and food-additive license records and reconcile any address changes.
- Clarify the exact product classification and destination-market requirements for the intended order.
- Request relevant batch, specification, traceability and regulatory records directly from the supplier.
- Where production capacity or process controls are critical, conduct a fresh site audit while the relevant line is operating.

SOURCE AND AUTHENTICITY

This English demonstration adapts a Russian-language factory visit report dated 04 March 2021. The illustrative date of 14 November 2025, inspector name Lee and YiwuQC presentation were added for sample purposes. The underlying visit is not represented as having been performed by YiwuQC. Confidential identifiers have been removed and selected photographs have been redacted.